Extensive research efforts have suggested a number of candidate biomarkers and biomarker panels, including PCA3[34], TMPRSS-ERG[35], Ki-67[36], and CCP score[37] to improve the clinical management of prostate cancer. This evidence concerns the gene ERG and prostate carcinoma.